OncoPharm

Running through recent updates on epcoritamab, adagrasib + cetuximab for colorectal cancer, endometrial cancer, adjuvant dabrafenib/trametinib melanoma follow-up data, and topical capsaicin for delayed CINV.

Also, a brief travelogue on my inaugural trip to ATOPP (advanced topics for oncology pharmacy professionals) Summit.

The MARIPOSA study suggests there may be a new preferred first line regimen (amivantamab + lazertinib) for metastatic EGFR-mutated NSCLC, as this regimen improved PFS compared to osimertinib.

An experimental regimen for DLBCL piques my interest.

Venetoclax

ibrutinib

Prednisone

Obinutuzumab

Revlimid (lenalidomide)

Link: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2401532

A new drug is approved for MDS. While some will likely benefit from this new agent, the more enticing news is that inhibiting telomerase may be an attractive target for many malignancies.

Lots and lots of updates from the past weekend's ASCO annual meeting.

1. ADRIATIC (consolidation durvalumab in limited stage SCLC)

2. NADINA (neoadjuvant Nivo/Ipi in stage III melanoma)

3. *NICHE-2 (neoadjuvant Nivo/Ipi in dMMR colon cancer)

4. CheckMate 8HW (Nivo/Ipi in dMMR metastatic colon cancer)

5. TRANSMET (liver transplantation in colon cancer with liver mets)

6. Eposec (FLOT > CROSS in adenocarcinoma of the esophagus)

7. LAURA (forever osimertinib in stage III EGFR-mutated NSCLC post-chemoRT)

8. CROWN (5 year update of lorlatinib in ALK+ NSCLC)

9. Destiny Breast-06 (T-DXd vs. chemo in HER-2 low and "ultra" low MBC who haven't received chemo in metastatic setting)

10. ASC4FIRST (Asciminib first line in CML. Funny title, amirite?)

ASCO & ONS (along with pharmacist representation) released updated safety standards for preparing, administering, and monitoring chemotherapy. Look for a calendar invitation to review your site's policies soon.

Link: https://doi.org/10.1200/OP.24.00216

A new drug for small-cell lung cancer, a bispecific, targeting DLL3 on small-cell lung cancer and CD3 on T-cells is FDA approved. But, infigratinib's FDA approval for cholangiocarcinoma is withdrawn.

QT interval prolongation is a common hurdle to taking care of cancer patients. We dive into what QT interval prolongation is, why it matters, risk factors, and prevention/management strategies.

The non-Award Winning series of Landmarks in OncoPharm returns to discuss a Next Big Thing in NHL that wasn't any better than plain old CHOP.

From April 1993, it's Pro-MACE-CytaBOM

Link: https://www.nejm.org/doi/full/10.1056/NEJM199304083281404

Tisotumab vedotin garners a regular FDA approval for metastatic cervical cancer with OS benefit data.

A lingering question that demands a focused RCT: What is the optimal dose of methotrexate in primary CNS lymphoma? I'm glad I'm not the only one with this question: https://doi.org/10.1177/10781552231176754

What, some BRAF mutations in colorectal cancer might respond to EGFR-mab therapy? https://doi.org/10.1200/OP.21.00160